About Us

Our Scope

Business Development among China/ASEAN/Korea in the field of Pharmaceuticals/Biotechnology:

Licensing of technology/product
Investment recruitment

Our Competitiveness

Regional: BD among China/ASEAN Worldwide to Asia
Early staged: BD based on innovativeness
Remote/non-F2F: introduction based on Connection

Leadership

Mr. YoungHoon (Nicholas) Cho,
Managing Partner: CEO

CEIBS (中欧国际工商学院 www.ceibs.edu) Global EMBA ongoing
Seoul National Univ. MS, ChungAng Univ. BS in Life Science
Simcere-Genexine (JV COO), Genexine (BD Director), JW Pharma, Samyang (Korea & US)

Your Environment

Early stage Biotech company

; its finance environment

ROI of Bio-industry is 7 times higher than that of automotive industry.
However major parts of investment focused on matured Biotech companies (7 years old ~).

Early stage biotech is hard to be invested in relevant stage and relevant amount.
Among 400 companies, only 2 companies may survive.

How to Navigate the Valley of Death

The Valley of Death may come 3 years after incorporation in the stage of GLP tox/safety.
Phase Ⅰ requires $ 1~2M / years, 5 years~ (in case of Korea).

Possible solutions

ⅰ)  Special listing of excellent technology companies on the KOSDAQ
ⅱ)  Investment from VC and Angel Awarded by Government Grant
ⅲ)  Early Stage Licensing-Out M&A



Ref-: The basics of preclinical drug development for neurodegenerative disease indications. Steinmetz KL, Spack EG - BMC Neurol (2009),

Technology focused IPO

  • Tech Excellence

  • • L/O performance
    • Funding by Strategic Investors
    • Collaborative research network
    • Originality of tech.
    • Government project performance
  • Tech & Develop. Capability
  • • Multiple Pipelines
    • Stage of clinical development
    • Commercialization capability of technology
  • R&D Capability

  • • Expertise of top management (CEO)
    • Track Record of core scientist(s)
  • Intellectual Property
  • • Patent status of proprietary technology
    • Freedom To Operate (FTO) of IP.
  • Commercial Value Creation
  • • Competitors’ status in market
    • Profit model based on Global /domestic competitiveness
    • Absolute market Size
  • Successful Next Funding

Implication

Licensing Out

Funding by Strategic Investor

Value Increase of Portfolio

Trial Collaboration

Overseas Partnership
with Strategic Investors
especially with Pharma

Our Service

Key Success Factors of early stage L/O

  • Maximize Asset value
  • • Categorization of Asset
    - Make it bigger
    • Open Deal Structure
    - FTE reward
    • Make it grow by PFC
    (Project Focusing Company)
  • Focus on L/O Market
  • • Focus on future market, not on existing products
    • Focus on their needs, not to our capability
    • Benchmarking


  • Deal Fluency
  • • Importance of Front Line
    - Pattern, Capability
    • Location of experts
    - China / Korea
    - Connection
  • L/O success in early stage,   Investment from strategic investors

Partnering History

  • ...

    Genexine’s Licensing deal for China rights on GX-E4, with Chemo-Wanbang in Fosun Group (2016).
    Currently in clinical study in China

  • ...

    Genexine’s licensing deal for ASEAN & Australia right on GX-E4 with Kalbe Group–ASEAN`s leading pharma (2015).
    Currently in Phase III, 7 countries including Australia

  • ...

    Genexine’s licensing deal for China rights on multi products With Tasgen in Tasly Group (2015). Listed on NASDAQ as I-Mab (2020), Lead product is in Phase II China

  • ...

    Genexine’s HPV DNA vaccine licensing With Simnogen in Simcere Group (2014).
    JV backed co-development

  • ...

    Samyang’s siRNA technology co-development agreement (2011).
    Samyang is a Korean conglomerate having Samyang Biopharma

  • ...

    BD activity collaboration Asia wide located in Shanghai / Hong Kong

Contact

Korea (HQ)

70 Saechang-ro, Suite#106-1303, Yongsan-gu, Seoul 04354, Korea
서울특별시 용산구 새창로 70, 106동 1303호, (우편번호 04354)

info@bdpartners-asia.com

China

602 Pengjiang Road, Building C, Suite 105, Shanghai 200072
上海市静安区彭江路602号C座105室 邮政编码 200072

info@bdpartners-asia.com